{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T21:57:58Z","timestamp":1785448678181,"version":"3.56.0"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T00:00:00Z","timestamp":1748822400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T00:00:00Z","timestamp":1748822400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP23K11940"],"award-info":[{"award-number":["JP23K11940"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-05053-6","type":"journal-article","created":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T08:04:00Z","timestamp":1748851440000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Potential surrogate endpoint for B-cell hematologic malignancy: A systematic review and meta-analysis"],"prefix":"10.1038","volume":"15","author":[{"given":"Satoshi","family":"Hirano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Hanada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,2]]},"reference":[{"key":"5053_CR1","unstructured":"Center for Drug Evaluation and Research & FDA. (2021). https:\/\/www.fda.gov\/drugs\/development-resources\/table-surrogate-endpoints-were-basis-drug-approval-or-licensure. Table of surrogate endpoints that were the basis of drug approval or licensure [Internet]."},{"key":"5053_CR2","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJMoa2115304","volume":"386","author":"H Tilly","year":"2022","unstructured":"Tilly, H. et al. Polatuzumab Vedotin in previously untreated diffuse large B-cell lymphoma. N Engl. J. Med. 386, 351\u2013363 (2022).","journal-title":"N Engl. J. Med."},{"key":"5053_CR3","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","volume":"380","author":"T Facon","year":"2019","unstructured":"Facon, T. et al. Daratumumab plus Lenalidomide and dexamethasone for untreated myeloma. N Engl. J. Med. 380, 2104\u20132115 (2019).","journal-title":"N Engl. J. Med."},{"key":"5053_CR4","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1016\/S1470-2045(21)00466-6","volume":"22","author":"T Facon","year":"2021","unstructured":"Facon, T. et al. Daratumumab, Lenalidomide, and dexamethasone versus Lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (Maia): overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 22, 1582\u20131596 (2021).","journal-title":"Lancet Oncol."},{"key":"5053_CR5","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1056\/NEJMoa1805104","volume":"379","author":"F Morschhauser","year":"2018","unstructured":"Morschhauser, F. et al. Rituximab plus Lenalidomide in advanced untreated follicular lymphoma. N Engl. J. Med. 379, 934\u2013947 (2018).","journal-title":"N Engl. J. Med."},{"key":"5053_CR6","doi-asserted-by":"publisher","first-page":"e069132","DOI":"10.1136\/bmjopen-2022-069132","volume":"13","author":"J Xie","year":"2023","unstructured":"Xie, J. et al. Comparison of novel oncology drugs that received dual approval from the US accelerated approval and EU conditional marketing authorisation pathways, 2006\u20132021: A cross-sectional study. BMJ Open. 13, e069132 (2023).","journal-title":"BMJ Open."},{"key":"5053_CR7","unstructured":"US Food and Drug Administration. Clinical trial considerations to support the accelerated approval of oncology therapeutics, (2023). https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/clinical-trial-considerations-support-accelerated-approval-oncology-therapeutics"},{"key":"5053_CR8","doi-asserted-by":"publisher","first-page":"2816","DOI":"10.1080\/10428194.2022.2095624","volume":"63","author":"K Broglio","year":"2022","unstructured":"Broglio, K. et al. PET-CR as a potential surrogate endpoint in untreated DLBCL: Meta-analysis and implications for clinical trial design. Leuk. Lymphoma. 63, 2816\u20132831 (2022).","journal-title":"Leuk. Lymphoma"},{"key":"5053_CR9","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1200\/JCO.19.00172","volume":"38","author":"LH Sehn","year":"2020","unstructured":"Sehn, L. H. et al. Polatuzumab Vedotin in relapsed or refractory diffuse large B-cell lymphoma. J. Clin. Oncol. 38, 155\u2013165 (2020).","journal-title":"J. Clin. Oncol."},{"key":"5053_CR10","doi-asserted-by":"publisher","first-page":"e0267979","DOI":"10.1371\/journal.pone.0267979","volume":"17","author":"P Daniele","year":"2022","unstructured":"Daniele, P. et al. Response rates and minimal residual disease outcomes as potential surrogates for progression-free survival in newly diagnosed multiple myeloma. PLOS One. 17, e0267979 (2022).","journal-title":"PLOS One"},{"key":"5053_CR11","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1182\/blood-2015-03-632430","volume":"126","author":"F Offner","year":"2015","unstructured":"Offner, F. et al. Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL. Blood 126, 1893\u20131901 (2015).","journal-title":"Blood"},{"key":"5053_CR12","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1182\/blood.2022018730","volume":"141","author":"JS Abramson","year":"2023","unstructured":"Abramson, J. S. et al. Lisocabtagene Maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study. Blood 141, 1675\u20131684 (2023).","journal-title":"Blood"},{"key":"5053_CR13","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1056\/NEJMoa2116596","volume":"386","author":"MR Bishop","year":"2022","unstructured":"Bishop, M. R. et al. Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma. N Engl. J. Med. 386, 629\u2013639 (2022).","journal-title":"N Engl. J. Med."},{"key":"5053_CR14","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1056\/NEJMoa2301665","volume":"389","author":"JR Westin","year":"2023","unstructured":"Westin, J. R. et al. Survival with Axicabtagene Ciloleucel in large B-cell lymphoma. N Engl. J. Med. 389, 148\u2013157 (2023).","journal-title":"N Engl. J. Med."},{"key":"5053_CR15","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa2116133","volume":"386","author":"FL Locke","year":"2022","unstructured":"Locke, F. L. et al. Axicabtagene Ciloleucel as second-line therapy for large B-cell lymphoma. N Engl. J. Med. 386, 640\u2013654 (2022).","journal-title":"N Engl. J. Med."},{"key":"5053_CR16","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1182\/bloodadvances.2022008802","volume":"7","author":"GAA Burke","year":"2023","unstructured":"Burke, G. A. A. et al. Ibrutinib plus RICE or RVICI for relapsed\/refractory mature B-cell non-Hodgkin lymphoma in children and young adults: SPARKLE trial. Blood Adv. 7, 602\u2013610 (2023).","journal-title":"Blood Adv."},{"key":"5053_CR17","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1200\/JCO.20.01366","volume":"39","author":"GS Nowakowski","year":"2021","unstructured":"Nowakowski, G. S. et al. ROBUST: A phase III study of Lenalidomide plus R-CHOP versus placebo plus R-CHOP in previously untreated patients with ABC-type diffuse large B-cell lymphoma. J. Clin. Oncol. 39, 1317\u20131328 (2021).","journal-title":"J. Clin. Oncol."},{"key":"5053_CR18","doi-asserted-by":"crossref","unstructured":"Dreyling, M. et al. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: An international, randomised, open-label, Phase 3 study. Lancet 387, 770\u2013778 Erratum in: Lancet 387, 750 (2016). (2016).","DOI":"10.1016\/S0140-6736(15)00667-4"},{"key":"5053_CR19","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13045-020-00900-7","volume":"13","author":"LH Sehn","year":"2020","unstructured":"Sehn, L. H. et al. A randomized, open-label, phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-cell lymphoma: final analysis of GOYA. J. Hematol. Oncol. 13, 71 (2020).","journal-title":"J. Hematol. Oncol."},{"key":"5053_CR20","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1016\/S1470-2045(18)30685-5","volume":"19","author":"T Robak","year":"2018","unstructured":"Robak, T. et al. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study. Lancet Oncol. 19, 1449\u20131458 (2018).","journal-title":"Lancet Oncol."},{"key":"5053_CR21","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1056\/NEJMoa1412096","volume":"372","author":"T Robak","year":"2015","unstructured":"Robak, T. et al. Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. N Engl. J. Med. 372, 944\u2013953 (2015).","journal-title":"N Engl. J. Med."},{"key":"5053_CR22","doi-asserted-by":"publisher","first-page":"e267","DOI":"10.1016\/S2352-3026(21)00022-3","volume":"8","author":"F Frontzek","year":"2021","unstructured":"Frontzek, F. et al. Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trial. Lancet Haematol. 8, e267\u2013e277 (2021).","journal-title":"Lancet Haematol."},{"key":"5053_CR23","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1016\/S1470-2045(12)70481-3","volume":"13","author":"N Schmitz","year":"2012","unstructured":"Schmitz, N. et al. Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1). Lancet Oncol. 13, 1250\u20131259 (2012).","journal-title":"Lancet Oncol."},{"key":"5053_CR24","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/S1470-2045(12)70212-7","volume":"13","author":"R Pettengell","year":"2012","unstructured":"Pettengell, R. et al. Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: A phase 3, multicentre, open-label, randomised trial. Lancet Oncol. 13, 696\u2013706 (2012). Erratum in: Lancet Oncol. 13, 696\u2013706 (2012).","journal-title":"Lancet Oncol."},{"key":"5053_CR25","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1200\/JCO.18.02403","volume":"37","author":"A Younes","year":"2019","unstructured":"Younes, A. et al. Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma. J. Clin. Oncol. 37, 1285\u20131295 (2019).","journal-title":"J. Clin. Oncol."},{"key":"5053_CR26","doi-asserted-by":"publisher","first-page":"5107","DOI":"10.1200\/JCO.23.00775","volume":"41","author":"PL Zinzani","year":"2023","unstructured":"Zinzani, P. L. et al. ROSEWOOD: A phase II randomized study of zanubrutinib plus obinutuzumab versus obinutuzumab monotherapy in patients with relapsed or refractory follicular lymphoma. J. Clin. Oncol. 41, 5107\u20135117 (2023).","journal-title":"J. Clin. Oncol."},{"key":"5053_CR27","doi-asserted-by":"publisher","first-page":"3990","DOI":"10.1200\/JCO.2011.34.8508","volume":"29","author":"T Watanabe","year":"2011","unstructured":"Watanabe, T. et al. Phase II\/III study of R-CHOP-21 versus R-CHOP-14 for untreated indolent B-cell non-Hodgkin\u2019s lymphoma: JCOG 0203 trial. J. Clin. Oncol. 29, 3990\u20133998 (2011).","journal-title":"J. Clin. Oncol."},{"key":"5053_CR28","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/S1470-2045(21)00145-5","volume":"22","author":"M Matasar","year":"2021","unstructured":"Matasar, M. et al. (ed, J.) Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): A double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 22 678\u2013689 (2021). Erratum in: Lancet Oncol. 22, 678\u2013689 (2021).","journal-title":"Lancet Oncol."},{"key":"5053_CR29","doi-asserted-by":"publisher","first-page":"7141","DOI":"10.1182\/bloodadvances.2023010298","volume":"7","author":"LJ Nastoupil","year":"2023","unstructured":"Nastoupil, L. J. et al. Phase 3 SELENE study: ibrutinib plus BR\/R-CHOP in previously treated patients with follicular or marginal zone lymphoma. Blood Adv. 7, 7141\u20137150 (2023).","journal-title":"Blood Adv."},{"key":"5053_CR30","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1200\/JCO.19.00010","volume":"37","author":"JP Leonard","year":"2019","unstructured":"Leonard, J. P. et al. AUGMENT: A phase III study of Lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma. J. Clin. Oncol. 37, 1188\u20131199 (2019).","journal-title":"J. Clin. Oncol."},{"key":"5053_CR31","doi-asserted-by":"publisher","first-page":"3886","DOI":"10.1182\/bloodadvances.2020001942","volume":"4","author":"DG Maloney","year":"2020","unstructured":"Maloney, D. G. et al. A phase 3 randomized study (homer) of ofatumumab vs rituximab in i-NHL relapsed after rituximab-containing therapy. Blood Adv. 4, 3886\u20133893 (2020).","journal-title":"Blood Adv."},{"key":"5053_CR32","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1111\/bjh.17420","volume":"193","author":"MJ Rummel","year":"2021","unstructured":"Rummel, M. J. et al. A phase 3, randomized study of ofatumumab combined with Bendamustine in rituximab-refractory iNHL (COMPLEMENT A\u2009+\u2009B study). Br. J. Haematol. 193, 1123\u20131133 (2021).","journal-title":"Br. J. Haematol."},{"key":"5053_CR33","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/S1470-2045(11)70150-4","volume":"12","author":"B Coiffier","year":"2011","unstructured":"Coiffier, B. et al. Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: A randomised phase 3 trial. Lancet Oncol. 12, 773\u2013784 (2011).","journal-title":"Lancet Oncol."},{"key":"5053_CR34","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.3324\/haematol.2022.282490","volume":"108","author":"B Puertas","year":"2023","unstructured":"Puertas, B. et al. Randomized phase II study of weekly Carfilzomib 70\u00a0mg\/m\u00b2 and dexamethasone with or without cyclophosphamide in relapsed and\/or refractory multiple myeloma patients. Haematologica 108, 2753\u20132763 (2023).","journal-title":"Haematologica"},{"key":"5053_CR35","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1200\/JCO.21.02815","volume":"41","author":"MA Dimopoulos","year":"2023","unstructured":"Dimopoulos, M. A. et al. Elotuzumab plus Pomalidomide and dexamethasone for relapsed\/refractory multiple myeloma: final overall survival analysis from the randomized phase II ELOQUENT-3 trial. J. Clin. Oncol. 41, 568\u2013578 (2023).","journal-title":"J. Clin. Oncol."},{"key":"5053_CR36","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1056\/NEJMoa1805762","volume":"379","author":"MA Dimopoulos","year":"2018","unstructured":"Dimopoulos, M. A. et al. Elotuzumab plus Pomalidomide and dexamethasone for multiple myeloma. N Engl. J. Med. 379, 1811\u20131822 (2018).","journal-title":"N Engl. J. Med."},{"key":"5053_CR37","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1111\/bjh.13582","volume":"171","author":"H Ludwig","year":"2015","unstructured":"Ludwig, H. et al. Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5-year follow-up. Br. J. Haematol. 171, 344\u2013354 (2015).","journal-title":"Br. J. Haematol."},{"key":"5053_CR38","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1200\/JCO.2011.39.5137","volume":"31","author":"H Ludwig","year":"2013","unstructured":"Ludwig, H. et al. Randomized phase II study of bortezomib, thalidomide, and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myeloma. J. Clin. Oncol. 31, 247\u2013255 (2013).","journal-title":"J. Clin. Oncol."},{"key":"5053_CR39","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa2303379","volume":"389","author":"J San-Miguel","year":"2023","unstructured":"San-Miguel, J. et al. Cilta-Cel or standard care in lenalidomide-refractory multiple myeloma. N Engl. J. Med. 389, 335\u2013347 (2023).","journal-title":"N Engl. J. Med."},{"key":"5053_CR40","doi-asserted-by":"publisher","first-page":"e801","DOI":"10.1016\/S2352-3026(23)00243-0","volume":"10","author":"MA Dimopoulos","year":"2023","unstructured":"Dimopoulos, M. A. et al. Efficacy and safety of Single-Agent Belantamab Mafodotin versus Pomalidomide plus Low-Dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): A phase 3, Open-Label, randomised study. Lancet Haematol. 10, e801\u2013e812 (2023).","journal-title":"Lancet Haematol."},{"key":"5053_CR41","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","volume":"388","author":"P Rodriguez-Otero","year":"2023","unstructured":"Rodriguez-Otero, P. et al. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N Engl. J. Med. 388, 1002\u20131014 (2023).","journal-title":"N Engl. J. Med."},{"key":"5053_CR42","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/s41408-023-00923-6","volume":"13","author":"T Martin","year":"2023","unstructured":"Martin, T. et al. Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized phase 3 study. Blood Cancer J. Blood Cancer J. 13, 152 (2023).","journal-title":"Blood Cancer J. Blood Cancer J."},{"key":"5053_CR43","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.clml.2023.02.009","volume":"23","author":"W Fu","year":"2023","unstructured":"Fu, W. et al. Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: the phase 3 OCTANS study. Clin. Lymphoma Myeloma Leuk. 23, 446\u2013455e4 (2023).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"5053_CR44","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.1016\/j.clml.2022.10.007","volume":"23","author":"W Fu","year":"2023","unstructured":"Fu, W. et al. Daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in Chinese patients with relapsed or refractory multiple myeloma: updated analysis of LEPUS. Clin. Lymphoma Myeloma Leuk. 23, e51\u2013e58 (2023).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"5053_CR45","doi-asserted-by":"publisher","first-page":"e813","DOI":"10.1016\/S2352-3026(23)00218-1","volume":"10","author":"MA Dimopoulos","year":"2023","unstructured":"Dimopoulos, M. A. et al. Subcutaneous daratumumab plus Pomalidomide and dexamethasone versus Pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trial. Lancet Haematol. 10, e813\u2013e824 (2023).","journal-title":"Lancet Haematol."},{"key":"5053_CR46","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/S1470-2045(21)00128-5","volume":"22","author":"MA Dimopoulos","year":"2021","unstructured":"Dimopoulos, M. A. et al. Daratumumab plus Pomalidomide and dexamethasone versus Pomalidomide and dexamethasone alone in previously treated multiple myeloma (Apollo): an Open-Label, randomised, phase 3 trial. Lancet Oncol. 22, 801\u2013812 (2021).","journal-title":"Lancet Oncol."},{"key":"5053_CR47","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S1470-2045(21)00579-9","volume":"23","author":"SZ Usmani","year":"2022","unstructured":"Usmani, S. Z. et al. Carfilzomib, dexamethasone, and daratumumab versus Carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, Open-Label, phase 3 study. Lancet Oncol. 23, 65\u201376 (2022).","journal-title":"Lancet Oncol."},{"key":"5053_CR48","doi-asserted-by":"crossref","unstructured":"Dimopoulos, M. et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma (CANDOR): Results from a Randomised, Multicentre, Open-Label, Phase 3 Study. Lancet 396, 186\u2013197 Erratum in: Lancet 396, 466 (2020). (2020).","DOI":"10.1016\/S0140-6736(20)30734-0"},{"key":"5053_CR49","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/S1470-2045(20)30525-8","volume":"21","author":"SK Kumar","year":"2020","unstructured":"Kumar, S. K. et al. Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): A randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 21, 1630\u20131642 (2020).","journal-title":"Lancet Oncol."},{"key":"5053_CR50","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/S0140-6736(20)32292-3","volume":"396","author":"S Grosicki","year":"2020","unstructured":"Grosicki, S. et al. Once-Per-Week selinexor, bortezomib, and dexamethasone versus Twice-Per-Week bortezomib and dexamethasone in patients with multiple myeloma (Boston): A randomised, Open-Label, phase 3 trial. Lancet 396, 1563\u20131573 (2020).","journal-title":"Lancet"},{"key":"5053_CR51","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/S1470-2045(18)30354-1","volume":"19","author":"P Moreau","year":"2018","unstructured":"Moreau, P. et al. Once weekly versus twice weekly Carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study. Lancet Oncol. 19, 953\u2013964 (2018). Erratum in: Lancet Oncol. 19, 953\u2013964 (2018).","journal-title":"Lancet Oncol."},{"key":"5053_CR52","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/S0140-6736(19)32956-3","volume":"395","author":"MV Mateos","year":"2020","unstructured":"Mateos, M. V. et al. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): A randomised, open-label, phase 3 trial. Lancet 395, 132\u2013141 (2020).","journal-title":"Lancet"},{"key":"5053_CR53","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1200\/JCO.21.02734","volume":"41","author":"P Sonneveld","year":"2023","unstructured":"Sonneveld, P. et al. Overall survival with daratumumab, bortezomib, and dexamethasone in previously treated multiple myeloma (CASTOR): A randomized, open-label, phase III trial. J. Clin. Oncol. 41, 1600\u20131609 (2023).","journal-title":"J. Clin. Oncol."},{"key":"5053_CR54","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1056\/NEJMoa1606038","volume":"375","author":"A Palumbo","year":"2016","unstructured":"Palumbo, A. et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl. J. Med. 375, 754\u2013766 (2016).","journal-title":"N Engl. J. Med."},{"key":"5053_CR55","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.3324\/haematol.2018.194118","volume":"103","author":"A Spencer","year":"2018","unstructured":"Spencer, A. et al. Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR. Haematologica 103, 2079\u20132087 (2018).","journal-title":"Haematologica"},{"key":"5053_CR56","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1200\/JCO.22.00940","volume":"41","author":"MA Dimopoulos","year":"2023","unstructured":"Dimopoulos, M. A. et al. Overall survival with daratumumab, lenalidomide, and dexamethasone in previously treated multiple myeloma (POLLUX): A randomized, open-label, phase III trial. J. Clin. Oncol. 41, 1590\u20131599 (2023).","journal-title":"J. Clin. Oncol."},{"key":"5053_CR57","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","volume":"375","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos, M. A. et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl. J. Med. 375, 1319\u20131331 (2016).","journal-title":"N Engl. J. Med."},{"key":"5053_CR58","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S1470-2045(19)30152-4","volume":"20","author":"PG Richardson","year":"2019","unstructured":"Richardson, P. G. et al. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with Lenalidomide (OPTIMISMM): A randomised, open-label, phase 3 trial. Lancet Oncol. 20, 781\u2013794 (2019).","journal-title":"Lancet Oncol."},{"key":"5053_CR59","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1182\/blood-2018-09-874396","volume":"133","author":"T Facon","year":"2019","unstructured":"Facon, T. et al. Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma. Blood 133, 1953\u20131963 (2019).","journal-title":"Blood"},{"key":"5053_CR60","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1200\/JCO.21.00972","volume":"39","author":"PG Richardson","year":"2021","unstructured":"Richardson, P. G. et al. Final overall survival analysis of the TOURMALINE-MM1 phase III trial of ixazomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma. J. Clin. Oncol. 39, 2430\u20132442 (2021).","journal-title":"J. Clin. Oncol."},{"key":"5053_CR61","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","volume":"374","author":"P Moreau","year":"2016","unstructured":"Moreau, P. et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl. J. Med. 374, 1621\u20131634 (2016).","journal-title":"N Engl. J. Med."},{"key":"5053_CR62","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/S1470-2045(17)30578-8","volume":"18","author":"MA Dimopoulos","year":"2017","unstructured":"Dimopoulos, M. A. et al. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (Endeavor): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncol. 18, 1327\u20131337 (2017). Erratum in: Lancet Oncol. 18, 1327\u20131337 (2017).","journal-title":"Lancet Oncol."},{"key":"5053_CR63","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","volume":"17","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos, M. A. et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (Endeavor): A randomised, phase 3, Open-Label, multicentre study. Lancet Oncol. 17, 27\u201338 (2016).","journal-title":"Lancet Oncol."},{"key":"5053_CR64","doi-asserted-by":"publisher","first-page":"e403","DOI":"10.1016\/S2352-3026(22)00103-X","volume":"9","author":"MA Dimopoulos","year":"2022","unstructured":"Dimopoulos, M. A. et al. Addition of elotuzumab to Lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial. Lancet Haematol. 9, e403\u2013e414 (2022).","journal-title":"Lancet Haematol."},{"key":"5053_CR65","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41408-020-00357-4","volume":"10","author":"MA Dimopoulos","year":"2020","unstructured":"Dimopoulos, M. A. et al. Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study. Blood Cancer J. 10, 91 (2020).","journal-title":"Blood Cancer J."},{"key":"5053_CR66","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1505654","volume":"373","author":"S Lonial","year":"2015","unstructured":"Lonial, S. et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl. J. Med. 373, 621\u2013631 (2015).","journal-title":"N Engl. J. Med."},{"key":"5053_CR67","doi-asserted-by":"publisher","first-page":"e506","DOI":"10.1016\/S2352-3026(16)30147-8","volume":"3","author":"JF San-Miguel","year":"2016","unstructured":"San-Miguel, J. F. et al. Overall survival of patients with relapsed multiple myeloma treated with Panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 Trial): A Randomised, placebo-Controlled, Phase 3 Trial. Lancet Haematol. 3, e506\u2013e515 (2016).","journal-title":"Lancet Haematol."},{"key":"5053_CR68","unstructured":"San-Miguel, J. F. et al. Panobinostat Plus bortezomib and dexamethasone versus Placebo Plus bortezomib and dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: A Multicentre, Randomised, double-blind Phase 3 trial. Lancet Oncol. 15, 1195\u20131206 Erratum in: Lancet Oncol. 16, e6 (2015). (2014)."},{"key":"5053_CR69","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1200\/JCO.2017.76.5032","volume":"36","author":"DS Siegel","year":"2018","unstructured":"Siegel, D. S. et al. Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma. J. Clin. Oncol. 36, 728\u2013734 (2018).","journal-title":"J. Clin. Oncol."},{"key":"5053_CR70","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1411321","volume":"372","author":"AK Stewart","year":"2015","unstructured":"Stewart, A. K. et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl. J. Med. 372, 142\u2013152 (2015).","journal-title":"N Engl. J. Med."},{"key":"5053_CR71","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/S1470-2045(13)70398-X","volume":"14","author":"M Dimopoulos","year":"2013","unstructured":"Dimopoulos, M. et al. Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): A multicentre, randomised, double-blind study. Lancet Oncol. 14, 1129\u20131140 (2013).","journal-title":"Lancet Oncol."},{"key":"5053_CR72","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","volume":"12","author":"P Moreau","year":"2011","unstructured":"Moreau, P. et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: A randomised, phase 3, Non-Inferiority study. Lancet Oncol. 12, 431\u2013440 (2011). Erratum in: Lancet Oncol. 12, 431\u2013440 (2011).","journal-title":"Lancet Oncol."},{"key":"5053_CR73","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1200\/JCO.2007.14.1853","volume":"26","author":"SV Rajkumar","year":"2008","unstructured":"Rajkumar, S. V. et al. Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. J. Clin. Oncol. 26, 2171\u20132177 (2008).","journal-title":"J. Clin. Oncol."},{"key":"5053_CR74","doi-asserted-by":"crossref","unstructured":"San Miguel, J. F. et al. J.F., San Miguel,. Persistent Overall Survival Benefit and No Increased Risk of Second Malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in Patients with Previously Untreated Multiple Myeloma. J. Clin. Oncol. 31, 448\u2013455. (2013).","DOI":"10.1200\/JCO.2012.41.6180"},{"key":"5053_CR75","doi-asserted-by":"crossref","unstructured":"San Miguel, J. F. et al. J.F., San Miguel,. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N. Engl. J. Med. 359, 906\u2013917. (2008).","DOI":"10.1056\/NEJMoa0801479"},{"key":"5053_CR76","doi-asserted-by":"publisher","first-page":"3616","DOI":"10.1182\/blood.2020008787","volume":"137","author":"T Facon","year":"2021","unstructured":"Facon, T. et al. Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma. Blood 137, 3616\u20133628 (2021).","journal-title":"Blood"},{"key":"5053_CR77","unstructured":"Food, U. S. & Administration, D. Meeting of the Oncologic Drugs Advisory Committee Meeting Announcement. (2024). https:\/\/www.fda.gov\/advisory-committees\/advisory-committee-calendar\/april-12-2024-meeting-oncologic-drugs-advisory-committee-meeting-announcement-04122024"},{"key":"5053_CR78","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1182\/blood.2024024371","volume":"144","author":"O Landgren","year":"2024","unstructured":"Landgren, O. et al. EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma. Blood 144, 359\u2013367 (2024).","journal-title":"Blood"},{"key":"5053_CR79","doi-asserted-by":"publisher","first-page":"101237","DOI":"10.1016\/j.blre.2024.101237","volume":"68","author":"JY Li","year":"2024","unstructured":"Li, J. Y., Zuo, L. P., Xu, J. & Sun, C. Y. Clinical applications of Circulating tumor DNA in hematological malignancies: from past to the future. Blood Rev. 68, 101237 (2024).","journal-title":"Blood Rev."},{"key":"5053_CR80","unstructured":"National Comprehensive Cancer Network Guideline. Multiple Myeloma. Version 4. (2024). https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1445"},{"key":"5053_CR81","doi-asserted-by":"crossref","unstructured":"Durie, B. G. et al. International uniform response criteria for multiple myeloma. Leukemia 20, 1467\u20131473 Erratum in: Leukemia 21, 1134 (2007). (2006).","DOI":"10.1038\/sj.leu.2404582"},{"key":"5053_CR82","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson, B. D. et al. Recommendations for initial evaluation, staging, and response assessment of hodgkin and non-Hodgkin lymphoma: the Lugano classification. J. Clin. Oncol. 32, 3059\u20133068 (2014).","journal-title":"J. Clin. Oncol."},{"key":"5053_CR83","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13643-021-01626-4","volume":"10","author":"MJ Page","year":"2021","unstructured":"Page, M. J. et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst. Rev. 10, 89 (2021).","journal-title":"Syst. Rev."},{"key":"5053_CR84","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1002\/sim.1187","volume":"21","author":"SG Thompson","year":"2002","unstructured":"Thompson, S. G. & Higgins, J. P. T. How should meta-regression analyses be undertaken and interpreted? Stat. Med. 21, 1559\u20131573 (2002).","journal-title":"Stat. Med."},{"key":"5053_CR85","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v036.i03","volume":"36","author":"W Viechtbauer","year":"2010","unstructured":"Viechtbauer, W. Conducting meta-analyses in R with the metafor package. J. Stat. Softw. 36, 1\u201348 (2010).","journal-title":"J. Stat. Softw."},{"key":"5053_CR86","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JPT Higgins","year":"2002","unstructured":"Higgins, J. P. T. & Thompson, S. G. Quantifying heterogeneity in a meta-analysis. Stat. Med. 21, 1539\u20131558 (2002).","journal-title":"Stat. Med."},{"key":"5053_CR87","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger, M., Davey Smith, G., Schneider, M. & Minder, C. Bias in meta-analysis detected by a simple, graphical test. BMJ 315, 629\u2013634 (1997).","journal-title":"BMJ"}],"updated-by":[{"DOI":"10.1038\/s41598-026-64373-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000}}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-05053-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-05053-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-05053-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T21:02:54Z","timestamp":1785445374000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-05053-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,2]]},"references-count":87,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5053"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-05053-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6104188\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,2]]},"assertion":[{"value":"25 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41598-026-64373-3","URL":"https:\/\/doi.org\/10.1038\/s41598-026-64373-3","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Satoshi Hirano is an employee of Kyowa Kirin Co. Ltd. The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study did not require institutional review board approval or informed patient consent because it was based on publicly available information and did not involve patient records.","order":2,"name":"Ethics","label":"Institutional review board statement","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"19300"}}